SEC Form 4 · accession 0000899243-15-006169
Aegerion Pharmaceuticals, Inc. · AEGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Benjamin Harshbarger
Officer — General Counsel and Secretary
Period of report
Oct 1, 2015
Accepted (ET)
Oct 5, 2015 · 4:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001338042
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $13.19 | Oct 1, 2015 | A | 30,000 | A | — | Oct 1, 2025 | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F1The stock option award has an exercise price equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant.
- F225% of the shares of common stock underlying this stock option award will vest on October 1, 2016. The remaining 75% of the shares of common stock underlying this stock option award will vest thereafter in equal monthly installments through October 1, 2019, subject to the Reporting Person's continued employment with the Issuer.